Alkem Laboratories Limited

rs,

11th November, 2022 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra K

₹ 30,793 million

umbai today. Key highlights of Q2FY23 financial performance • Total Revenue from Operations was ₹ 30,793 million, year-on-year growth of 10.0% India sales were ₹ 22,161 million, year-on-year growth of 13.0% Int

10.0%

inancial performance • Total Revenue from Operations was ₹ 30,793 million, year-on-year growth of 10.0% India sales were ₹ 22,161 million, year-on-year growth of 13.0% International sales were ₹ 8,291

₹ 22,161 million

Total Revenue from Operations was ₹ 30,793 million, year-on-year growth of 10.0% India sales were ₹ 22,161 million, year-on-year growth of 13.0% International sales were ₹ 8,291 million, year-on-year growth of 3.0

13.0%

93 million, year-on-year growth of 10.0% India sales were ₹ 22,161 million, year-on-year growth of 13.0% International sales were ₹ 8,291 million, year-on-year growth of 3.0% o o • Earnings before

₹ 8,291 million

of 10.0% India sales were ₹ 22,161 million, year-on-year growth of 13.0% International sales were ₹ 8,291 million, year-on-year growth of 3.0% o o • Earnings before Interest, Tax, Depreciation and Amortizati

3.0%

ion, year-on-year growth of 13.0% International sales were ₹ 8,291 million, year-on-year growth of 3.0% o o • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 4,539 milli

₹ 4,539 million

rowth of 3.0% o o • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 4,539 million, resulting in EBITDA margin of 14.7% vs. 22.3% in Q2FY22. EBITDA declined by 27.3% YoY • R&D expe

14.7%

st, Tax, Depreciation and Amortization (EBITDA) was ₹ 4,539 million, resulting in EBITDA margin of 14.7% vs. 22.3% in Q2FY22. EBITDA declined by 27.3% YoY • R&D expenses for the quarter was ₹ 1,305 milli

22.3%

epreciation and Amortization (EBITDA) was ₹ 4,539 million, resulting in EBITDA margin of 14.7% vs. 22.3% in Q2FY22. EBITDA declined by 27.3% YoY • R&D expenses for the quarter was ₹ 1,305 million, or 4.2

27.3%

) was ₹ 4,539 million, resulting in EBITDA margin of 14.7% vs. 22.3% in Q2FY22. EBITDA declined by 27.3% YoY • R&D expenses for the quarter was ₹ 1,305 million, or 4.2% of total revenue from operations

₹ 1,305 million

rgin of 14.7% vs. 22.3% in Q2FY22. EBITDA declined by 27.3% YoY • R&D expenses for the quarter was ₹ 1,305 million, or 4.2% of total revenue from operations compared to ₹ 1,407 million in Q2FY22 at 5.0% of total

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 101 1573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7969718&linkS ecurityString=25aba0ffbe You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com About Alkem Laboratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in